With the help of clinical genetic testing of tumors, the use of Berry Gene Sequencer has expanded.

(Health Times network end of the reporter Wen Wei)
. At present, with NGS (second generation sequencing technology, next generation sequencing) as the platform, noninvasive DNA prenatal testing (NIPT) has become an important clinical prenatal screening method. Clinically, tumor, genetic disease, reproductive health and other fields can also be used through genetic testing technology for clinically assisted diagnosis, disease monitoring, disease early screening and individualized drug use, biopharmaceutical research and development.On July 7,
, Berry Gene announced that the application of its NextSeq CN500 gene sequencer had been approved by the National Drug Administration. This means that NextSeq CN500 has crossed NIPT into clinical genetic testing of human diseases, becoming a ready-to-ground medical facility, and an NGS general purpose platform for large-scale clinical genetic testing.Berry Gene CEO Zhou Daixing
clinical applications in the field of cancer is of great concern
according to the latest data released by the National Cancer Center in January this year, there were about 3.929 million new cases of malignant tumors in China in 2015, with an average of more than 10,000 people diagnosed with cancer every day, and the overall burden of cancer continues to rise.
this nextSeq CN500 application change, the most attention is its clinical application in the field of oncology. "To some extent, many front-line medical institutions are expecting this expansion as much as Berry's own." Dr. Gao Yang, chairman of Berry Gene, said.Gao Yang, chairman ofBerry Gene,
forecast that the total size of the NGS application market is US$20 billion, of which the oncology field accounts for 60% to US$12 billion, which is the most important application area.
the application of genetic testing in the field of tumors, including early screening, molecular distype, drug guidance, prognosis monitoring and so on. Especially in the field of cancer treatment, such as targeted drugs, genetic testing plays an important role. It is an internationally recognized and effective means to achieve precise treatment of tumors and early screening through the study of genomics. Because it can not only improve the efficiency of treatment, but also reduce the individual and social health care burden of patients.Clinical genetic testing of tumors in
hospitals can be immediately
most of the ngS medical genetic testing data in the world are now derived from the NextSeq platform. NextSeq CN500 is developed specifically for hospitals, with easy operation, large throughput, high data quality, low detection costs and so on. Listed so far, has entered more than 100 qualified medical institutions in China, and access to market recognition, is one of the few, well-functioning NGS sequencer.
the approval of NextSeq CN500NextSeq CN500, it will no doubt accelerate the clinical popularization of tumor genetic detection, as well as accelerate the development of accurate diagnostic methods for tumor drugs and tumors.
", "In nextSeq CN500, a common platform, Berry Gene will strictly comply with relevant laws and regulations, fully consider social needs, integrate domestic and foreign first-class research and development resources, through independent research and development and strategic cooperation, the development of more commercial value of precision medical solutions, to further meet the clinical needs of patients and medical institutions." In his presentation, Dr. Gao Yang introduced the development plan around NextSeq CN500.
Berry Gene and member enterprises and Swiss Gene, has been actively layout of the early screening of tumor early diagnosis market, currently leading not only the national science and technology research on major scientific and technological research, but also with the National Center for Cancer Science / Guangzhou Southern Hospital to carry out a 10,000-person liver cancer prospective research, one of the important work is to work with domestic experts to clinical transformation of these research results. Therefore, in the near future, NextSeq CN500 will greatly accelerate the clinical promotion of these research results, so that the results of the research more quickly benefit the public.
invited li Jinming Researcher of the Clinical Testing Center of the National Health And Health Commission, Professor Yu Jinming of Shandong Cancer Hospital, Professor Yu Lingxuan of the Center for Medical Genetics of Central South University, Professor Yu Tangchun of Tongji Medical College of Huazhong University of Science and Technology, and more than 40 experts and scholars from all over the country, and discussed the clinical application and future development trend of NGS technology.
.